# KEYNOTE-224 (NCT02702414)

> Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02702414
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Hepatocellular Carcinoma
- Interventions: Pembrolizumab
- Enrollment: 156
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on KEYNOTE-224 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- YouTube: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-224-nct02702414

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02702414", "email": "<work email>"}; the inbox owner confirms by the emailed link.